CN110960562A - 抗敏作用的益生菌组合物 - Google Patents
抗敏作用的益生菌组合物 Download PDFInfo
- Publication number
- CN110960562A CN110960562A CN201911424065.8A CN201911424065A CN110960562A CN 110960562 A CN110960562 A CN 110960562A CN 201911424065 A CN201911424065 A CN 201911424065A CN 110960562 A CN110960562 A CN 110960562A
- Authority
- CN
- China
- Prior art keywords
- lactobacillus casei
- group
- lactobacillus
- effect
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000003266 anti-allergic effect Effects 0.000 title claims abstract description 13
- 239000000203 mixture Substances 0.000 title claims abstract description 12
- 239000006041 probiotic Substances 0.000 title claims abstract description 9
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 9
- 230000000529 probiotic effect Effects 0.000 title claims abstract description 8
- 230000000694 effects Effects 0.000 title abstract description 21
- 244000199866 Lactobacillus casei Species 0.000 claims abstract description 33
- 235000013958 Lactobacillus casei Nutrition 0.000 claims abstract description 33
- 229940017800 lactobacillus casei Drugs 0.000 claims abstract description 33
- 240000006024 Lactobacillus plantarum Species 0.000 claims abstract description 15
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims abstract description 15
- 229940072205 lactobacillus plantarum Drugs 0.000 claims abstract description 15
- 150000001875 compounds Chemical class 0.000 claims abstract description 6
- 239000002068 microbial inoculum Substances 0.000 claims abstract description 6
- 241000186660 Lactobacillus Species 0.000 claims abstract description 4
- 229940039696 lactobacillus Drugs 0.000 claims abstract description 4
- 235000013305 food Nutrition 0.000 claims abstract description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 3
- 238000004321 preservation Methods 0.000 claims abstract description 3
- 239000007788 liquid Substances 0.000 claims description 14
- 239000002775 capsule Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 208000003251 Pruritus Diseases 0.000 abstract description 15
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 32
- 235000014655 lactic acid Nutrition 0.000 description 16
- 239000004310 lactic acid Substances 0.000 description 15
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 14
- 239000013641 positive control Substances 0.000 description 12
- 230000001580 bacterial effect Effects 0.000 description 10
- 210000002784 stomach Anatomy 0.000 description 9
- 208000026935 allergic disease Diseases 0.000 description 8
- 241000214517 Lactobacillus casei group Species 0.000 description 6
- 230000007803 itching Effects 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000002500 effect on skin Effects 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000012353 t test Methods 0.000 description 3
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 235000013351 cheese Nutrition 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 229940119744 dextran 40 Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/125—Casei
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
试验前IgE(ng /mL) | 试验后IgE(ng /mL) | |
空白组 | 3.15±0.42 | 5.31±2.11 |
阳性对照组 | 2.64±0.30 | 51.24±8.28 |
LP45干预组 | N.D | 47.28±11.40<sup>1</sup> |
干酪乳杆菌LC-N235干预组 | 1.5±0.41 | 46.23±5.71<sup>1</sup> |
LP45+ LC-N235干预组 | N.D | 12.74±6.44<sup>2</sup> |
LP45+乳酸干预组 | 1.98±0.62 | 48.21±8.43<sup>1</sup> |
LP45+普通干酪干预组 | 1.01±0.71 | 43.28±13.22<sup>1</sup> |
瘙痒次数 | 瘙痒阈值/s | |
空白组 | 30.10±7.63 | 98.32±18.32 |
阳性对照组 | 10.04±3.33 | 243.24±22.35 |
LP45干预组 | 25.77±5.73<sup>2</sup> | 103.85±13.58<sup>2</sup> |
干酪乳杆菌LC-N235干预组 | 29.50±8.48<sup>2</sup> | 123.29±15.88<sup>2</sup> |
LP45+ LC-N235干预组 | 12.51±3.41<sup>1</sup> | 222.74±22.94<sup>1</sup> |
LP45+乳酸干预组 | 28.24±5.23<sup>2</sup> | 107.85±20.57<sup>2</sup> |
LP45+普通干酪干预组 | 26.24±5.23<sup>2</sup> | 102.22±17.50<sup>2</sup> |
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911424065.8A CN110960562B (zh) | 2019-12-31 | 2019-12-31 | 抗敏作用的益生菌组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911424065.8A CN110960562B (zh) | 2019-12-31 | 2019-12-31 | 抗敏作用的益生菌组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110960562A true CN110960562A (zh) | 2020-04-07 |
CN110960562B CN110960562B (zh) | 2020-10-16 |
Family
ID=70037836
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911424065.8A Active CN110960562B (zh) | 2019-12-31 | 2019-12-31 | 抗敏作用的益生菌组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110960562B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111733203A (zh) * | 2020-06-02 | 2020-10-02 | 青岛复诺生物医疗有限公司 | 一种***顶体反应检测方法 |
WO2022095287A1 (zh) * | 2020-11-06 | 2022-05-12 | 拉格比(广东)健康科技有限公司 | 一种改善过敏性体质的益生菌滴剂 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102653725A (zh) * | 2012-05-30 | 2012-09-05 | 南京工业大学 | 一种凝结芽孢杆菌及其在混合发酵产l-乳酸中的应用 |
CN102653724A (zh) * | 2012-05-30 | 2012-09-05 | 南京工业大学 | 一株干酪乳杆菌及其在发酵产l-乳酸中的应用 |
CN103642716A (zh) * | 2013-11-21 | 2014-03-19 | 河北一然生物科技有限公司 | 一种植物乳杆菌及其应用 |
CN110494551A (zh) * | 2017-01-31 | 2019-11-22 | 庆熙大学校产学协力团 | 新型乳酸菌及其用途 |
-
2019
- 2019-12-31 CN CN201911424065.8A patent/CN110960562B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102653725A (zh) * | 2012-05-30 | 2012-09-05 | 南京工业大学 | 一种凝结芽孢杆菌及其在混合发酵产l-乳酸中的应用 |
CN102653724A (zh) * | 2012-05-30 | 2012-09-05 | 南京工业大学 | 一株干酪乳杆菌及其在发酵产l-乳酸中的应用 |
CN103642716A (zh) * | 2013-11-21 | 2014-03-19 | 河北一然生物科技有限公司 | 一种植物乳杆菌及其应用 |
CN110494551A (zh) * | 2017-01-31 | 2019-11-22 | 庆熙大学校产学协力团 | 新型乳酸菌及其用途 |
Non-Patent Citations (1)
Title |
---|
周晶等: "三株乳酸杆菌益生及免疫特性研究 ", 《食品工业》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111733203A (zh) * | 2020-06-02 | 2020-10-02 | 青岛复诺生物医疗有限公司 | 一种***顶体反应检测方法 |
WO2022095287A1 (zh) * | 2020-11-06 | 2022-05-12 | 拉格比(广东)健康科技有限公司 | 一种改善过敏性体质的益生菌滴剂 |
Also Published As
Publication number | Publication date |
---|---|
CN110960562B (zh) | 2020-10-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102365414B1 (ko) | 락토바실러스 파라카제이 균주 및 그 용도 | |
CN102835657B (zh) | 用以抑制发炎反应及抗***炎的含乳酸菌食品组合物及医药组合物 | |
JP2021524748A (ja) | ラクトバチルス・ガッセリーkbl697株及びその使用 | |
WO2022110727A1 (zh) | 副干酪乳杆菌et-22提升肠道细菌感染抗性和肠道免疫力的应用 | |
CN111956671A (zh) | 一种用于治疗幽门螺旋杆菌感染的复合益生菌 | |
CN112914103A (zh) | 一种抗幽门螺杆菌感染的益生菌组合物及其应用 | |
JP7442195B2 (ja) | ラクトバチルス・クリスパタスkbl693株及びその使用 | |
CN110960562B (zh) | 抗敏作用的益生菌组合物 | |
CN114149939B (zh) | 一种能够缓解龋齿的益生菌组合物及其应用 | |
KR101379404B1 (ko) | 황금 발효물 및 이를 포함하는 항균 및 면역 증강 조성물 | |
CN115813971B (zh) | 一种用于治疗急性中耳炎的黄芪饮片及其制备方法 | |
CN111254088A (zh) | 一种凝结芽孢杆菌菌株及其应用 | |
CN114908020A (zh) | 一种抗幽门螺旋杆菌感染的植物乳杆菌及其在食用本草酵素产品中的应用 | |
CN114287633B (zh) | 含蔓越莓的益生菌组合物及其在抗幽门螺旋杆菌中的应用 | |
CN110484459B (zh) | 一株植物乳杆菌及其应用 | |
KR101396842B1 (ko) | 오미자 발효물 및 이를 포함하는 항균 및 면역 증강 조성물 | |
CN115119940A (zh) | 嗜酸乳杆菌LA85和乳双歧杆菌BLa80在抑制幽门螺旋杆菌上的应用 | |
CN114836349B (zh) | 拮抗幽门螺旋杆菌的嗜酸乳杆菌la16及其应用 | |
CN111296842B (zh) | 一种具有抗敏作用的益生菌组合物 | |
US20220313756A1 (en) | Method for alleviating helicobacter pylori-associated disorder using culture of lactic acid bacterial strain | |
WO2022134658A1 (zh) | 一株能够预防、缓解银屑病的短双歧杆菌及其应用 | |
CN114908004A (zh) | 一种能够预防和/或治疗特应性皮炎的婴儿双歧杆菌及其应用 | |
CN116731913B (zh) | 植物乳植杆菌在制备抗幽门螺杆菌产品中的应用 | |
KR101164512B1 (ko) | 비피도박테리움 슈도카테눌라튬 spm1204 유산균 또는 이의 배양물을 유효성분으로 하는 가축용 생균제 조성물 | |
US11801274B2 (en) | Method for alleviating atopic dermatitis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20200917 Address after: 511400 Room 201, Building 19, Tian'an Headquarters Center, 555 North Panyu Avenue, Donghuan Street, Panyu District, Guangzhou City, Guangdong Province Applicant after: GUANGZHOU AIBAIYI BIOLOGY TECHNOLOGY Co.,Ltd. Address before: Room 612-13, No. 2999 Ziyang Avenue, Nanchang High-tech Industrial Development Zone, Nanchang City, Jiangxi Province Applicant before: Nanchang Norway Pharmaceutical Technology Co.,Ltd. |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20221020 Address after: Room 301 and Room 401, Building 1, No. 17, Fuxing Jinhe First Road, Hualong Town, Panyu District, Guangzhou City, Guangdong Province, 510663 Patentee after: Guangdong Nuopin Health Industry Co.,Ltd. Address before: Room 201, building 19, Tian'an headquarters center, 555 Panyu Avenue North, Donghuan street, Panyu District, Guangzhou City, Guangdong Province Patentee before: GUANGZHOU AIBAIYI BIOLOGY TECHNOLOGY CO.,LTD. |
|
TR01 | Transfer of patent right |